The short term safety of COVID-19 vaccines in Australia: AusVaxSafety active surveillance, February – August 2021

To assess the short term safety of the COVID-19 vaccines Comirnaty (Pfizer–BioNTech BNT162b2) and Vaxzevria (AstraZeneca ChAdOx1) in Australia.

Citation:
Deng L, Glover C, Dymock M, Pillsbury A, Marsh JA … et al. The short term safety of COVID-19 vaccines in Australia: AusVaxSafety active surveillance, February – August 2021. Med J Aust. 2022

Keywords:
COVID-19; Drug-related side effects and adverse reactions; Vaccination

Abstract:
To assess the short term safety of the COVID-19 vaccines Comirnaty (Pfizer–BioNTech BNT162b2) and Vaxzevria (AstraZeneca ChAdOx1) in Australia.